Kurt Werner Schmid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2510017/publications.pdf

Version: 2024-02-01

51 papers

1,052 citations

430874 18 h-index 30 g-index

52 all docs 52 docs citations

52 times ranked 2048 citing authors

#	Article	IF	Citations
1	Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine, 2022, 75, 293-302.	2.3	8
2	Abandoning node dissection for desmoplasia-negative encapsulated unifocal sporadic medullary thyroid cancer. Surgery, 2022, 171, 360-367.	1.9	10
3	Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy. BMC Cancer, 2022, 22, 46.	2.6	6
4	CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer. Frontiers in Oncology, 2022, 12, 798680.	2.8	10
5	Clonidine suppression test for a reliable diagnosis of pheochromocytoma: When to use. Clinical Endocrinology, 2022, 97, 541-550.	2.4	6
6	Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior. International Journal of Molecular Sciences, 2022, 23, 3278.	4.1	5
7	Pulmonary echinococcosis: A rare pseudotumour of the lung. Rare Tumors, 2021, 13, 203636132110097.	0.6	3
8	Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity. Cancers, 2021, 13, 1761.	3.7	5
9	Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study. Translational Lung Cancer Research, 2021, 10, 3030-3042.	2.8	1
10	Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension. BMC Endocrine Disorders, 2021, 21, 161.	2.2	4
11	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. Frontiers in Oncology, 2021, 11, 725549.	2.8	6
12	Therapeutic Effect of Combined Dabrafenib and Trametinib Treatment of BRAF V600E-Mutated Primary Squamous Cell Carcinoma of the Thyroid: A Case Report. European Thyroid Journal, 2021, 10, 511-516.	2.4	4
13	Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma – Lessons From Individual Cases With Long-Term Follow-Up. Frontiers in Endocrinology, 2021, 12, 718418.	3.5	4
14	The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma – systematic review and discussion of current therapeutic options. Wspolczesna Onkologia, 2021, 25, 213-223.	1.4	7
15	Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. Scientific Reports, 2020, 10, 16533.	3.3	12
16	Urachal Cancer in Germany and the USA: An RKI/SEER Population-Based Comparison Study. Urologia Internationalis, 2020, 104, 803-809.	1.3	12
17	A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint Inhibition. Cancer Management and Research, 2020, Volume 12, 7881-7890.	1.9	6
18	Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma. Scientific Reports, 2020, 10, 18677.	3.3	10

#	Article	IF	CITATIONS
19	<p>Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma</p> . Cancer Management and Research, 2019, Volume 11, 8711-8720.	1.9	10
20	Intranuclear inclusions in hepatocellular carcinoma contain autophagyâ€associated proteins and correlate with prolonged survival. Journal of Pathology: Clinical Research, 2019, 5, 164-176.	3.0	10
21	Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer, 2019, 19, 108.	2.6	28
22	Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy. Journal of Oncology, 2019, 2019, 1-11.	1.3	1
23	<p>Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response</p> . Cancer Management and Research, 2019, Volume 11, 9571-9583.	1.9	17
24	Setting out the frame conditions for feasible use of FFPE derived RNA. Pathology Research and Practice, 2019, 215, 381-386.	2.3	11
25	Immunohistochemically Detectable Metallothionein Expression in Malignant Pleural Mesotheliomas is Strongly Associated with Early Failure to Platin-Based Chemotherapy. , 2019, 73, .		0
26	<scp>P</scp> athogenic and targetable genetic alterations in 70 urachal adenocarcinomas. International Journal of Cancer, 2018, 143, 1764-1773.	5.1	44
27	Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. Oncotarget, 2018, 9, 22254-22268.	1.8	9
28	Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1143-1154.	2.5	43
29	Intermediate microRNA expression profile in Graves' disease falls between that of normal thyroid tissue and papillary thyroid carcinoma. Journal of Clinical Pathology, 2017, 70, 33-39.	2.0	11
30	miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 627-637.	2.8	22
31	Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1659-1670.	2.5	2
32	Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. European Journal of Cancer, 2017, 86, 248-256.	2.8	63
33	NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget, 2017, 8, 42613-42620.	1.8	69
34	Molecular dissection of effector mechanisms of <i>RAS</i> -mediated resistance to anti-EGFR antibody therapy. Oncotarget, 2017, 8, 45898-45917.	1.8	12
35	Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. Journal of Cancer, 2016, 7, 1915-1925.	2.5	18
36	ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology. PLoS ONE, 2016, 11, e0165181.	2.5	34

#	Article	IF	Citations
37	Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine, 2016, 54, 733-741.	2.3	41
38	Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. World Journal of Surgical Oncology, 2016, 14, 189.	1.9	100
39	microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. Oncotarget, 2016, 7, 18713-18721.	1.8	16
40	Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Oncotarget, 2016, 7, 20166-20179.	1.8	11
41	Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. British Journal of Cancer, 2015, 113, 1704-1711.	6.4	61
42	<i>SOX4</i> , <i>SOX11</i> and <i>PAX6</i> mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString). Future Oncology, 2015, 11, 1027-1036.	2.4	25
43	Morphological and clinical presentation of papillary thyroid carcinoma in children and adolescents of Belarus: The influence of radiation exposure and the source of irradiation. Experimental and Molecular Pathology, 2015, 98, 527-531.	2.1	24
44	Histopathology of C Cells and Medullary Thyroid Carcinoma. Recent Results in Cancer Research, 2015, 204, 41-60.	1.8	26
45	Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis. Oncotarget, 2015, 6, 24690-24698.	1.8	15
46	Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours. Journal of Cancer, 2014, 5, 646-654.	2.5	27
47	Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study. Modern Pathology, 2014, 27, 1632-1640.	5 . 5	71
48	TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation Journal of Clinical Oncology, 2014, 32, 8109-8109.	1.6	1
49	Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients. PLoS ONE, 2014, 9, e85350.	2.5	51
50	EORTC trial 11001: distribution of two ¹⁰ Bâ€compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. Journal of Cellular and Molecular Medicine, 2009, 13, 1653-1665.	3 . 6	38
51	Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors). Human Pathology, 2009, 40, 1706-1714.	2.0	19